Amgen (AMGN) said Thursday said that a phase 3 trial of its Uplizna drug showed "durable and sustained efficacy" in patients with acetylcholine receptor autoantibody-positive generalized myasthenia gravis with just two doses a year following an initial loading dose.
The company said the study showed that 72.3% of AChR+ patients treated with Uplizna achieved an improvement of at least 3 points in the Myasthenia Gravis Activities of Daily Living score, compared with 45.2% in placebo.
Amgen previously said the trial, which also evaluated muscle-specific kinase autoantibody-positive patients, met its primary endpoint of statistically significant change from baseline in MG-ADL score at week 26 for both the MuSK+ and AChR+ patients taking Uplizna.
The company said it expects to complete filing its application for Uplizna in gMG in H1. The US Food and Drug Administration granted Orphan Drug Designation for Uplizna in gMG.
The drug is currently approved for the treatment of adults with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder and is under priority review by the FDA for Immunoglobulin G4-related disease with a target action date of April 3.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。